Nav: Home

Investigation reveals how the NHS is impeding access to high-priced drugs

July 27, 2016

An investigation published by The BMJ today reveals how the NHS is impeding access to high priced drugs for hepatitis C.

Researchers from the University of Cambridge and the University of Bath, and The BMJ, show how NHS England, unable to budget for broad access to these drugs, tried to alter the outcome of the NICE process, and when it failed, defied NICE's authority by rationing access to them.

The investigation also exposes key weaknesses in our current system of assessing the value of new therapies and delivering them to patients - and asks, is company pricing to blame?

Hepatitis C is a virus that can infect the liver. There are an estimated 214,000 individuals chronically infected in the UK which, if left untreated, can cause life-threatening liver damage.

In 2014, two new drugs for hepatitis C infection were launched (Sovaldi and Harvoni, manufactured by Gilead Sciences) - offering cure rates of over 90%. But with prices ranging from around $90,000 per patient in the US to almost £35,000 in England and 41,000 euro in France, they have sparked a global debate about access to high priced medicines for governments with limited resources.

During the course of this investigation, it has emerged how apparent panic over high prices and affordability led NHS England to deploy many delaying tactics, which succeeded in hampering timely access to these drugs.

For Sovaldi, NHS England spuriously asked for six months to implement guidance (the mandatory 90 days and an additional three months), saying it needed time to set up a proper database to audit patients and usage of the new drugs.

NHS England also tried to completely block Harvoni and two other competitor drugs undergoing appraisals at NICE, and questioned the level of clinical evidence.

Andrew Ustianowski, a consultant in infectious diseases at Pennine Acute Hospitals NHS Trust, says: "I think some people in NHS England would love to clip NICE's wings and turn it into a kind of recommendatory rather than mandatory body. And if you are going to choose a fight then choosing this battlefield is quite a sensible thing to do - a marginalised population, very high-cost drugs."

Dr Ustianowski resigned from NHS England's clinical advisory group, in protest at deliberate attempts to delay access to treatment. "I didn't want to be associated with what was happening," he told The BMJ.

NICE did eventually succeed in publishing guidance recommending these drugs for the majority of hepatitis C patients. But NHS England is not fully following NICE's mandate, which requires that approved drugs are made available within the NHS.

Instead it has restricted use of the new drugs by forcing quotas on clinical teams around the country.

This rationing has left many clinicians facing hard decisions and difficult conversations with patients who have already seen their treatments delayed several times. And there is now growing evidence that some frustrated patients are turning to overseas "buyers' clubs" to source the drugs at their own expense.

NHS England says its delivery of drugs is entirely within the parameters of the NICE guidance - and highlighted Gilead's pricing as the key reason why treatment was being delayed.

This echoes major criticisms of Gilead's pricing strategy in the US, where legislators said the company had adopted a strategy "designed to maximise revenue with little concern for access or affordability."

So why didn't NHS England strike a better pricing deal with Gilead? Under current rules, NHS England is unable to negotiate specific deals with individual drug companies.

A spokesperson for NHS England said it was "exploring the potential for a longer term strategic procurement for a supply agreement with the industry to improve the affordability of and access to treatment further."

Whatever the reason for the failure to achieve broad access to the new hepatitis drugs in England, the Hepatitis C Trust, a patient advocacy organisation, believes the NHS is risking legal action over its decision to ration them. Chief Executive, Charles Gore, said the Trust has "already spoken to solicitors to take on any cases that come up, because we are not going to have NHS England pick on a disenfranchised group."

In a linked analysis, researchers argue that the acquisition strategies of drug companies magnify development costs and leave the public paying twice - for research and high priced medicines.

Solutions, they say, include giving health systems increased power to negotiate pricing and payment models, limiting share buybacks, and testing other ways to encourage and reward drug development.

In a linked editorial, Professor Mariana Mazzucato at the University of Sussex discusses why government must negotiate a better deal for publicly funded research.

She believes that an effective pricing system "should ensure accessibility but also reflect the public contribution so taxpayers don't pay twice, through publicly subsidised research and high priced medicines." Importantly, she adds, "drug pricing must be completely transparent, so that governments can negotiate for better value on behalf of their populations."
-end-
About BMJ

BMJ is a healthcare knowledge provider that aims to advance healthcare worldwide by sharing knowledge and expertise to improve experiences, outcomes and value. For a full list of BMJ products and services, please visit bmj.com

BMJ

Related Hepatitis Articles:

Hepatitis C increasing among pregnant women
Hepatitis C infections among pregnant women nearly doubled from 2009-2014, likely a consequence of the country's increasing opioid epidemic that is disproportionately affecting rural areas of states including Tennessee and West Virginia.
WHO's Global Hepatitis Report sets baseline to eliminate viral hepatitis by 2030
The World Hepatitis Alliance today welcomes the publication of the first-ever Global Hepatitis Report by the World Health Organization (WHO), which includes new data on the prevalence and global burden of viral hepatitis.
Elimination of viral hepatitis by 2030: What's needed and how do we get there?
This first European Action Plan provides an important driver to aid countries in their fight against viral hepatitis, to which ECDC had the opportunity to contribute directly.
Discovery of new Hepatitis C virus mechanism
Researchers at Osaka University, Japan uncovered the mechanisms that suppress the propagation of the hepatitis C virus with the potential of improving pathological liver conditions.
Is Europe ready to eliminate viral hepatitis?
Currently, Europe records around 57,000 newly diagnosed acute and chronic cases of hepatitis B and C each year.
Why baby boomers need a hepatitis C screening
Hepatitis C affects a disproportionate amount of older Americans, born between 1945 and 1965.
Counterattack of the hepatitis B virus
The hepatitis B virus (HBV) infects liver cells. Drugs are available to treat HBV, but they rarely cure the infection, and so the virus typically returns after the treatment ends.
Hepatitis C tied to increased risk of Parkinson's
The hepatitis C virus may be associated with an increased risk of developing Parkinson's disease, according to a study published in the Dec.
The hepatitis A virus is of animal origin
The hepatitis A virus can trigger acute liver inflammation which generally has a mild course in small children but which can become dangerous in adults.
Modeling the helicase to understand hepatitis C
NS3 is an enzyme specific to the hepatitis C virus.

Related Hepatitis Reading:

Best Science Podcasts 2019

We have hand picked the best science podcasts for 2019. Sit back and enjoy new science podcasts updated daily from your favorite science news services and scientists.
Now Playing: TED Radio Hour

Anthropomorphic
Do animals grieve? Do they have language or consciousness? For a long time, scientists resisted the urge to look for human qualities in animals. This hour, TED speakers explore how that is changing. Guests include biological anthropologist Barbara King, dolphin researcher Denise Herzing, primatologist Frans de Waal, and ecologist Carl Safina.
Now Playing: Science for the People

#SB2 2019 Science Birthday Minisode: Mary Golda Ross
Our second annual Science Birthday is here, and this year we celebrate the wonderful Mary Golda Ross, born 9 August 1908. She died in 2008 at age 99, but left a lasting mark on the science of rocketry and space exploration as an early woman in engineering, and one of the first Native Americans in engineering. Join Rachelle and Bethany for this very special birthday minisode celebrating Mary and her achievements. Thanks to our Patreons who make this show possible! Read more about Mary G. Ross: Interview with Mary Ross on Lash Publications International, by Laurel Sheppard Meet Mary Golda...